Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 259

1.

Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.

Acquaviva J, Jun HJ, Lessard J, Ruiz R, Zhu H, Donovan M, Woolfenden S, Boskovitz A, Raval A, Bronson RT, Pfannl R, Whittaker CA, Housman DE, Charest A.

Cancer Res. 2011 Dec 1;71(23):7198-206. doi: 10.1158/0008-5472.CAN-11-1514. Epub 2011 Oct 10.

PMID:
21987724
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.

Xing WJ, Zou Y, Han QL, Dong YC, Deng ZL, Lv XH, Jiang T, Ren H.

Clin Exp Pharmacol Physiol. 2013 Jan;40(1):13-21. doi: 10.1111/1440-1681.12026.

PMID:
23110505
[PubMed - indexed for MEDLINE]
3.

Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.

Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, Vandenberg SR, Zhou H, Marie SK, Mischel PS, Cavenee WK, Furnari FB.

Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14164-9. doi: 10.1073/pnas.1211962109. Epub 2012 Aug 13.

PMID:
22891331
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme.

Jun HJ, Acquaviva J, Chi D, Lessard J, Zhu H, Woolfenden S, Bronson RT, Pfannl R, White F, Housman DE, Iyer L, Whittaker CA, Boskovitz A, Raval A, Charest A.

Oncogene. 2012 Jun 21;31(25):3039-50. doi: 10.1038/onc.2011.474. Epub 2011 Oct 24.

PMID:
22020333
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.

Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ.

Cancer Res. 2009 Mar 15;69(6):2540-9. doi: 10.1158/0008-5472.CAN-08-1547. Epub 2009 Mar 10.

PMID:
19276385
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis.

Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R, Bronson RT, Chen JW, Weissleder R, Housman DE, Charest A.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2712-6. doi: 10.1073/pnas.0813314106. Epub 2009 Feb 5.

PMID:
19196966
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc.

Kim HS, Woolard K, Lai C, Bauer PO, Maric D, Song H, Li A, Kotliarova S, Zhang W, Fine HA.

Cancer Res. 2012 Nov 15;72(22):6065-75. doi: 10.1158/0008-5472.CAN-12-2594. Epub 2012 Sep 17.

PMID:
22986743
[PubMed - indexed for MEDLINE]
Free Article
8.

ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.

Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D.

Cancer Res. 2006 Aug 1;66(15):7473-81.

PMID:
16885344
[PubMed - indexed for MEDLINE]
Free Article
9.

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.

Mol Cancer Ther. 2009 Jul;8(7):1751-60. doi: 10.1158/1535-7163.MCT-09-0188. Epub 2009 Jul 7.

PMID:
19584231
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.

Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG.

Neoplasia. 2009 May;11(5):448-58, 2 p following 458.

PMID:
19412429
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS.

Cancer Discov. 2011 Oct;1(5):442-56. doi: 10.1158/2159-8290.CD-11-0102. Epub 2011 Sep 15. Erratum in: Cancer Discov. 2012 Feb;2(2):290-1.

PMID:
22059152
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.

Yacoub A, Mitchell C, Hong Y, Gopalkrishnan RV, Su ZZ, Gupta P, Sauane M, Lebedeva IV, Curiel DT, Mahasreshti PJ, Rosenfeld MR, Broaddus WC, James CD, Grant S, Fisher PB, Dent P.

Cancer Biol Ther. 2004 Aug;3(8):739-51. Epub 2004 Aug 10.

PMID:
15197348
[PubMed - indexed for MEDLINE]
Free Article
14.

Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.

Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, Yamanaka K, Ono M, Nakagawa K.

Mol Cancer Ther. 2012 Jan;11(1):204-13. doi: 10.1158/1535-7163.MCT-11-0638. Epub 2011 Nov 10.

PMID:
22075159
[PubMed - indexed for MEDLINE]
Free Article
15.

EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.

Geoerger B, Gaspar N, Opolon P, Morizet J, Devanz P, Lecluse Y, Valent A, Lacroix L, Grill J, Vassal G.

Int J Cancer. 2008 Jul 1;123(1):209-16. doi: 10.1002/ijc.23488.

PMID:
18386816
[PubMed - indexed for MEDLINE]
16.

PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.

Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, Ferris RL, Grandis JR, Zhang L, Yu J.

Oncogene. 2009 Jun 18;28(24):2348-57. doi: 10.1038/onc.2009.108. Epub 2009 May 4.

PMID:
19421143
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.

Guillamo JS, de Bo√ľard S, Valable S, Marteau L, Leuraud P, Marie Y, Poupon MF, Parienti JJ, Raymond E, Peschanski M.

Clin Cancer Res. 2009 Jun 1;15(11):3697-704. doi: 10.1158/1078-0432.CCR-08-2042. Epub 2009 May 12.

PMID:
19435839
[PubMed - indexed for MEDLINE]
Free Article
18.

Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.

Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS.

Cancer Res. 2006 Aug 15;66(16):7864-9.

PMID:
16912159
[PubMed - indexed for MEDLINE]
Free Article
19.

EGFR signaling is differentially activated in patient-derived glioblastoma stem cells.

Howard BM, Gursel DB, Bleau AM, Beyene RT, Holland EC, Boockvar JA.

J Exp Ther Oncol. 2010;8(3):247-60.

PMID:
20734923
[PubMed - indexed for MEDLINE]
20.

Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.

Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M.

Endocr Relat Cancer. 2005 Dec;12(4):983-98.

PMID:
16322337
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk